Is gliclazide a sulfonylurea with difference? A review in 2016

Expert Review of Clinical Pharmacology

Volumn 9, Issue 6, 2016, Pages 839-851

  Singh, Awadhesh Kumar ^a   Singh, Ritu ^a  

^a GD Hospital and Diabetes Institute   (India)

Author keywords

cardiovascular mortality; gliclazide; hypoglycemia; Ramadan; Sulfonylureas

Indexed keywords

ACARBOSE; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; GLIMEPIRIDE; GLIMEPIRIDE PLUS METFORMIN; GLIPIZIDE; GLIQUIDONE; INSULIN; ISOPHANE INSULIN; METFORMIN; NATEGLINIDE; PHENFORMIN; PIOGLITAZONE; REPAGLINIDE; SITAGLIPTIN; TOLBUTAMIDE; VILDAGLIPTIN; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR MORTALITY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPOGLYCEMIA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MUSLIM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); AGED; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

ADMINISTRATION, ORAL; AGED; DIABETES MELLITUS, TYPE 2; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; SULFONYLUREA COMPOUNDS;

EID: 84961216295     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1159512     Document Type: Review

References (93)

1. L.L.Brunton, B.A.Chabner, B.C.Knollmann, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 12th ed. New York (NY): McGraw-Hill Professional, The McGraw-Hill Companies, Inc.; 2010.
2. D.Sola, L.Rossi, G.P.Schianca, et al. State of the art paper Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;4(4):840–848.• This recent review evaluated the mechanism of action and pharmacological characteristics of SUs.
3. P.Proks, F.Reimann, N.Green, et al. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51:S368–S376.•• This study evaluated the receptor characteristics of different SUs.
4. I.Baczko, Z.Husti, V.Lang, et al. Sarcolemmal KATP channel modulators and cardiac arrhythmias. Curr Med Chem. 2011;18:3640–3661.
5. M.M.Mocanu, H.L.Maddock, G.F.Baxter, et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103:3111–3116.
6. S.J.Kim, H.Zhang, I.Khaliulin, et al. Activation of glibenclamide-sensitive ATP-sensitive K+ channels during β-adrenergically induced metabolic stress produces a substrate for atrial tachyarrhythmia. Circulation. 2012;5:1184–1192.
7. A.S.Abdelmoneim, S.E.Hasenbank, J.M.Seubert, et al. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab. 2012;14:130–138.• This study studied the tissue specificity of different SUs.
8. S.E.Inzucchi, R.M.Bergenstal, J.B.Buse, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
9. National Collaborating Centre for Chronic Conditions (UK). Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). National Institute for Health and Clinical Excellence: Guidance. London: Royal College of Physicians, 2008.
10. G.E.H.M.Rutten, W.J.C.De Grauw, G.Nijpels, et al. NHG-standaard diabetes mellitus type 2 (derde herziening). Huisarts Wet. 2013;56:512–525. [in Dutch]
11. WHO. 19th expert committee on the selection and use of essential medicines. World Health Organization; 2013 [updated 2013 Apr 8–12; cited 2015 Dec31]. Available from: http://www.who.int/selection_medicines/committees/expert/19/reviews/Glibenclamide_Rev2. pdf?ua=1.
12. J.P.Hosker, A.S.Rudenski, M.A.Burnett, et al. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism. 1989;38:767–772.
13. F.M.Gribble, F.Reimann Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complicat. 2003;17:11–15.• This study evaluated the differential action of different secretagogues.
14. M.Monami, C.Luzzi, C.Lamanna, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev. 2006;22(6):477–482.•• This was one of the first landmark study suggesting differential outcome with SUs in combination to metformin.
15. M.Monami, D.Balzi, C.Lamanna, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev. 2007;23:479–484.•• This study found difference in cancer mortality outcome with gliclazide compared to other SUs.
16. H.T.Horsdal, S.P.Johnsen, F.Søndergaard, et al. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: apopulation-based follow-up study. Diabetes Metab Res Rev. 2009;25:515–522.
17. M.Khalangot, M.Tronko, V.Kravchenko, et al. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract. 2009;86:247–253.
18. K.M.Pantalone, M.W.Kattan, C.Yu, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care. 2010;33:1224–1229.•• Although this study found no difference in outcome with 3 SUs, glimepiride monotherapy had better outcome compared to other SUs in those patient with known coronary disease.
19. M.Zeller, N.Danchin, D.Simon, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010;95:4993–5002.
20. C.H.Jørgensen, G.H.Gislason, C.Andersson, et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention–a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54.
21. T.K.Schramm, G.H.Gislason, A.Vaag, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900–1908.•• This landmark observational study found significantly better outcome with gliclazide compared to other SUs.
22. C.Andersson, G.H.Gislason, C.H.Jorgensen, et al. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract. 2011;94:119–125.
23. K.M.Pantalone, M.W.Kattan, C.Yu, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab. 2012;14(9):803–809.
24. S.Bo, A.Castiglione, E.Ghigo, et al. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. Eur J Endocrinol. 2013;169:117–126.
25. A.S.Abdelmoneim, D.T.Eurich, J.M.Gamble, et al. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. Diabetes Obes Metab. 2014;16(1):22–29.
26. Y.H.Lee, C.J.Lee, H.S.Lee, et al. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes Metab. 2015;41(3):208–215.• This study found no difference between glimepiride and gliclazide; however, gliclazide arm showed better outcome in doubling of serum creatinine and progression to end-stage renal disease especially in older patient.
27. S.H.Simpson, J.Lee, S.Choi, et al. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015;3(1):43–51.•• This network meta-analysis gliclazide having best mortality outcome compared to other SUs.
28. J.Gram, J.Jespersen. Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients. Am J Med. 1991;90:S62–S66.
29. A.Sliwinska, A.Rogalska, M.Szwed, et al. Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells. Mol Biol Rep. 2012;39:5253–5267.
30. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60:850–886.
31. S.Baba, S.Nakagawa, K.Takebe, et al. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes. Tohoku J Exp Med. 1983;141(Suppl):693–706.• This study appeared to be first one that compared gliclazide with glibenclamide and found better outcome with gliclazide.
32. K.M.Shaw, M.S.Wheeley, D.B.Campbell, et al. Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial. Diabetic Med. 1985;2:484–490.
33. A.D.Harrower. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin. 1985;9:676–680.•• This landmark study compared different SUs and found clear difference among SUs both in efficacy and safety.
34. G.Jerums, R.M.Murray, E.Seeman, et al. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study. Diabetes Res Clin Pract. 1987;3:71–80.
35. A.M.Jennings, R.M.Wilson, J.D.Ward. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 1989;12(3):203–208.
36. A.D.B.Harrower, C.Wong. Comparison of secondary failure rate between three second generation sulphonylureas. Diabetes Res. 1990;13:19–21.
37. A.D.Harrower. Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM. Diabetes Res Clin Pract. 1991;14(Suppl 2):S65–S67.• This review clearly finds superiority of gliclazide over other SUs.
38. J.Satoh, K.Takahashi, Y.Takizawa, et al. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract. 2005;70:291–297.
39. K.Maedler, R.D.Carr, D.Bosco, et al. Sulfonylurea induced β-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90:501–506.
40. D.Tessier, K.Dawson, J.P.Tetrault, et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med. 1994;11:974–980.
41. T.van Staa, L.Abenhaim, J.Monette. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997;50(6):735–741.
42. G.Schernthaner, A.Grimaldi, U.Di Mario, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34:535–542.•• This landmark study found similar glycemic control with gliclazide and glimepiride; however, hypoglycemia was significantly lower with gliclazide MR.
43. P.Kardas. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005;7:722–728.
44. K.Inukai, M.Watanabe, Y.Nakashima, et al. Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Res Clin Pract. 2005;68(3):250–257.
45. A.D.Harrower. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf. 2000;22(4):313–320.
46. A.S.Gangji, T.Cukierman, H.C.Gerstein, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30(2):389–394.• This systematic review found highest hypoglycemia with glibenclamide.
47. A.Collier, H.H.Watson, A.W.Patrick, et al. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabete Metab. 1989;15:420–425.
48. J.Noury, A.Nandeuil. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabete Metab. 1991;17:209–212.
49. D.Tessier, P.Maheux, A.Khalil, et al. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism. 1999;48:897–903.
50. N.Guvener, O.Gedik. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol. 1999;36:93–97.
51. S.Salman, F.Salman, I.Satman, et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin. 2001;16:296–306.
52. N.J.Furlong, S.A.Hulme, S.V.O’Brien, et al. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabet Med. 2003;20:935–941.
53. S.Ristic, C.Collober-Maugeais, E.Pecher, et al. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med. 2006;23:757–762.
54. Comparison of repaglinide and gliclazide in Chinese subjects with Type 2 diabetes never received oral antidiabetic drug treatment. 2010. Available from: http://clinicaltrialsgov/ct2/show/NCT01022762?term=NCT01022762&rank=1.
55. J.M.Lawrence, J.Reid, G.J.Taylor, et al. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early Type 2 diabetes. Diabetes Care. 2004;27:41–46.
56. B.H.Charbonnel, D.R.Matthews, G.Schernthaner, et al. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005;22:399–405.
57. D.R.Matthews, B.H.Charbonnel, M.Hanefeld, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167–174.
58. G.Perriello, S.Pampanelli, C.Di Pietro, et al. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabet Med. 2006;23:246–252.
59. J.E.Foley, S.Sreenan. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with Type 2 diabetes. Horm Metab Res. 2009;41:905–909.• This study compared gliclazide with vildagliptin and found less hypoglycemia with vildagliptin.
60. C.Filozof, J.F.Gautier. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabetic Med. 2010;27:318–326.
61. G.W.D.Landman, G.H.de Bock, K.J.J.van Hateren, et al. Safety and efficacy of gliclazide as treatment for Type 2 diabetes: a systematic review and meta-analysis of randomized trials. PLoS ONE. 2014;9(2):e82880. doi:10.1371/journal.pone.0082880.•• This large meta-analysis found gliclazide having edge over other SUs.
62. J.E.Schopman, A.C.R.Simon, S.J.M.Hoefnagel, et al. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014;30:11–22.•• This meta-analysis found least hypoglycemia with gliclazide.
63. D.Devendra, B.Gohel, V.Bravis, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract. 2009;63(10):1446–1450.
64. A.H.Zargar, M.Siraj, A.A.Jawa, et al. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast. Int J Cin Pract. 2010;64(8):1090–1094.
65. S.R.Aravind, K.Al Tayeb, S.B.Ismail, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011;27(6):1237–1242.
66. M.Hassanein, W.Hanif, W.Malik, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011;27(7):1367–1374.
67. M.Al-Arouj, A.A.Hassoun, R.Medlej, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract. 2013;67(10):957–963.• This large observational found higher hypoglycemia with SUs compared to vildagliptin.
68. S.Al Sifri, A.Basiounny, A.Echtay, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011;65(11):1132–1140.•• First RCT conducted during Ramadan suggested lower hypoglycemia with sitagliptin compared to SUs.
69. S.R.Aravind, S.B.Ismail, R.Balamurugan, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012;28(8):1289–1296.
70. M.Hassanein, K.Abdallah, A.Schweizer. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014;10:319–326.
71. J.C.Mbanya, S.Al-Sifri, A.Abdel-Rahim, et al. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP- 4 inhibitors during Ramadan: a meta-analytical approach. Diabetes Res Clin Pract. 2015;109:226–232. doi:10.1016/j.diabres.2015.04.030.•• Meta-analysis of RCT conducted during Ramadan suggesting similar hypoglycemia with gliclazide compared to DPP-4 inhibitors.
72. University Group Diabetes Program. A study of the eff ects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19(Suppl 2):747–830.
73. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
74. J.Olsson, G.Lindberg, M.Gottsäter, et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia. 2000 May;43(5):558–560.
75. E.Mannucci, M.Monami, G.Masotti, et al. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev. 2004;20(1):44–47.
76. J.M.Evans, S.A.Ogston, A.Emslie-Smith, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006 May;49(5):930–936.
77. I.Tzoulaki, M.Nolokhia, V.Curcin, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. Bmj. 2009;339:b4731.
78. J.A.Johnson, S.R.Majumdar, S.H.Simpson, et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25(12):2244–2248.
79. M.Gulliford, R.Latinovic. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev. 2004 May-Jun;20(3):239–245.
80. B.Sillars, W.A.Davis, I.B.Hirsch, et al. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab. 2010 Sep;12(9):757–765.
81. K.M.Pantalone, M.W.Kattan, C.Yu, et al. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis. Diabet Med. 2012;29(8):1029–1035.
82. A.D.Rao, N.Kuhadiya, K.Reynolds, et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: A meta-analysis of observational studies. Diabetes Care. 2008 Aug;31(8):1672–1678.•• This meta-analysis found no increased risk of mortality with SUs and metformin combination therapy.
83. S.P.Johnsen, T.B.Monster, M.L.Olsen, et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006;13(2):134–140.
84. S.M.Sadikot, C.E.Mogensen. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract. 2008;82(3):391–395.
85. A.M.Arruda-Olson, R.K.Patch, C.L.Leibson, et al. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clinic Proceedings. 2009;84:28–33.• This study found no difference among SUs on mortality outcome those admitted with myocardial infarction.
86. D.N.Juurlink, T.Gomes, B.R.Shah, et al. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. Diabet Med. 2012;29(12):1524–1528.
87. J.Nagendran, G.Y.Oudit, J.A.Bakal, et al. Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes? Diabetes Obes Metab. 2013;15:1022–1028.
88. Y.Huang, A.S.Abdelmoneim, P.Light, et al. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. J Diabetes Complications. 2015;29(2):196–202.
89. A.Patel, S.MacMahon, J.Chalmers, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
90. S.Zoungas, B.E.De Galan, T.Ninomiya, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068–2074.
91. [cited 2016 Jan 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01794143?term=GRADE+study&rank=2
92. J.Rosenstock, N.Marx, S.E.Kahn, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res. 2013;10(4):289–301.
93. O.Vaccaro, M.Masulli, E.Bonora, et al. TOSCA.IT study group. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutr Metab Cardiovasc Dis. 2012;22(11):997–1006.